Download PDF
Neuropediatrics 1993; 24(6): 332-336
DOI: 10.1055/s-2008-1071566
Original article

© Georg Thieme Verlag KG Stuttgart · New York

Lamotrigine in Resistant Childhood Epilepsy

Dina  Battino1 , Daniela  Buti2 , D.  Croci1 , Margherita  Estienne1 , A.  Fazio3 , Tiziana  Granata1 , F.  Pisani3 , Mariangela  Rota2 , G.  Avanzini1
  • 1Neurological Institute C. Besta, Milan, Italy
  • 2Epilepsy Center, Pediatric Department, University of Florence, Florence, Italy
  • 3Institute of Neurology, University of Messina, Messina, Italy
Further Information

Publication History

Publication Date:
19 March 2008 (online)

  PDF Download  Permissions and Reprints

Abstract

Fourteen children (6 M, 8 F) suffering from refractory epilepsy received LTG as add-on therapy. LTG was administered twice daily at dosages increasing up to 2 mg/kg/day (for patients taking VPA) or to 10 mg/kg/day for patients taking AEDs that induce hepatic metabolism. The drug was withdrawn for side effects in 3 cases (rash: two cases, hirsutism: one), because of increased seizure frequency in 2 cases and because of unchanged seizure frequency in one. One patient died from acute respiratory failure, after repeated respiratory tract infections.

A decrease in seizure frequency after one year of treatment with LTG was observed in 6 of the 7 patients who completed the study. The median total seizure frequency decreased from 10.7 ± 7.3 to 3.8 ± 4.6 seizures per day. At the end of the study, seizure frequency had decreased by more than 50 % in 2 patients, by more than 75 % in 2 patients, and 2 patients were seizure-free; in the remaining patient seizure frequency was unchanged.

The best results were obtained with plasma LTG concentrations ranging from 0.5 to 5.4 µg/ml; no further improvement was observed at higher LTG concentrations.

Abbreviations

LTG: lamotrigine
AEDs: antiepileptic drugs
VPA: sodium valproate
CBZ: carbamazepine
PRM: primidone
:PB: phenobarbital

Key words

Lamotrigine - Epilepsy - Anticonvulsants

      >